Skip to content

Umbilical Cord Mesenchymal Stem Cells Injection for Ocular Corneal Burn

Placebo-Controlled,Randomized,Double-blind Trial of Umbilical Cord Mesenchymal Stem Cells Injection for Ocular Corneal Burn

Status
UNKNOWN
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03237442
Enrollment
100
Registered
2017-08-02
Start date
2018-01-01
Completion date
2019-06-30
Last updated
2017-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular Corneal Burn

Brief summary

Ocular chemical burn is one of the causes of vision loss in China, and there are no satisfactory treatment. Human umbilical cord mesenchymal stem cells(UC-MSCs) have the biological characteristics of self-renewal, immune regulation, multidirectional differentiation and tissue repair. Our preliminary research showed that in corneal alkali injury rabbits, the UC-MSCs can accelerated the cornea repair, inhibited angiogenesis. The aim of this study is to access the efficacy and safety of UC-MSCs in the treatment of corneal burn in human.

Interventions

BIOLOGICALhuman umbilical cord mesenchymal stem cells

human UC-MSCs: 0.2ml(about 2\*10\^6 cells) subconjunctival injection

BIOLOGICALplacebo

Saline injection

Sponsors

Guangzhou Saliai Stem Cell Science and Technology Co. Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* must be ocular burns including chemically burned or the thermally burned; * the subjects are willing to accept this research, and promise to coordinate with the researchers during the follow up period; * the subjects should abide by the laws and rules of the study.

Exclusion criteria

* the visual acuity is blind in any of the eye; * have corneal perforation or have the corneal perforation tendency; * have been accepted surgery on eyeball after trauma; * IOP\>=25 mmHg even after antiglaucoma; * have the history of other corneal disease or surgery; * have the history of radiotherapy or surgery in the eyeball; * associated with corneal ulcer or endoophthalmitis; * uncontrolled hypertension(\>=150/95 mmHg); * abnormal liver and renal function; * the pregnant women.

Design outcomes

Primary

MeasureTime frame
the percent of cornea perforation3 months

Countries

China

Contacts

Primary ContactWanling Chen
chenwanling@saliai.com0086-20-37792600

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026